![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Background
Serum levels of gastrin-17 (S-G-17) and pepsinogen I (S-PGI) are biomarkers of gastric antral and corpus mucosa, respectively. We determined whether these tests, together with the assay of Helicobacter pylori antibodies, are a nonendoscopic tool for the diagnosis of atrophic gastritis.
Objectives
To study the relation between H. pylori infection and atrophic gastritis in the elderly through the estimation of gastrin 17 and pepsinogen I as novel noninvasive diagnostic biomarkers.
Material and methods
The present study included sixty individuals suffering from gastritis there were divided into two groups. Group (I): Thirty patients having H. pylori infection aged above 65 years. Group (II): Thirty patients without H. pylori infection aged above 65 years. All individuals were subjected to diagnostic upper-gastrointestinal endoscopy and specific gastric biomarkers (serum gastrin-17, serum pepsinogen I/II).
Results
Serum pepsinogen I, II, ratio and gastrin 17 decrease with increasing grade of atrophy of the antrum respectively. Serum pepsinogen I, II, gastrin 17 were significantly lower in mild, moderate, and severe gastritis compared to superficial gastritis patients.
Conclusion
The diagnosis of atrophic gastritis obtained with the blood test panel of G.17, SPG I/II and H. pylori antibodies is in good agreement with the endoscopic and biopsy finding. The panel is a tool for nonendoscopic diagnosis and screening of atrophic gastritis.
Notes
Peer review under responsibility of Alexandria University Faculty of Medicine.
Available online 1 September 2012